CYXO Stock Overview
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cyxone AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.097 |
| 52 Week High | kr0.78 |
| 52 Week Low | kr0.078 |
| Beta | 0.22 |
| 1 Month Change | 18.00% |
| 3 Month Change | -21.14% |
| 1 Year Change | -86.87% |
| 3 Year Change | -97.95% |
| 5 Year Change | -96.67% |
| Change since IPO | -98.48% |
Recent News & Updates
Shareholder Returns
| CYXO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 8.5% | 2.5% | -0.7% |
| 1Y | -86.9% | -3.4% | 4.4% |
Price Volatility
| CYXO volatility | |
|---|---|
| CYXO Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CYXO's share price has been volatile over the past 3 months.
Volatility Over Time: CYXO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Kjell Stenberg | www.cyxone.com |
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
Cyxone AB (publ) Fundamentals Summary
| CYXO fundamental statistics | |
|---|---|
| Market cap | kr20.94m |
| Earnings (TTM) | -kr22.99m |
| Revenue (TTM) | kr5.15m |
4.1x
P/S Ratio-0.9x
P/E RatioIs CYXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYXO income statement (TTM) | |
|---|---|
| Revenue | kr5.15m |
| Cost of Revenue | kr0 |
| Gross Profit | kr5.15m |
| Other Expenses | kr28.14m |
| Earnings | -kr22.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -446.56% |
| Debt/Equity Ratio | 0% |
How did CYXO perform over the long term?
See historical performance and comparison